{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:53:04Z","timestamp":1791341584689,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA193235"],"award-info":[{"award-number":["R01CA193235"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA255813"],"award-info":[{"award-number":["R01CA255813"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01CA265748"],"award-info":[{"award-number":["P01CA265748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA125123"],"award-info":[{"award-number":["CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180672"],"award-info":[{"award-number":["RP180672"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"U.S. Department of Health & Human Services | NIH | National Center for Research Resources","doi-asserted-by":"publisher","award":["RR024574"],"award-info":[{"award-number":["RR024574"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-025-02850-w","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:24:06Z","timestamp":1768213446000},"page":"511-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8475-7179","authenticated-orcid":false,"given":"Jing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-7314","authenticated-orcid":false,"given":"Dian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangguo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6010-7094","authenticated-orcid":false,"given":"Daisuke","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2850_CR1","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477\u201387.","journal-title":"N Engl J Med"},{"key":"2850_CR2","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"2850_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.exphem.2019.12.005","volume":"83","author":"KY King","year":"2020","unstructured":"King KY, Huang Y, Nakada D, Goodell MA. Environmental influences on clonal hematopoiesis. Exp Hematol. 2020;83:66\u201373.","journal-title":"Exp Hematol"},{"key":"2850_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","volume":"28","author":"D Hormaechea-Agulla","year":"2021","unstructured":"Hormaechea-Agulla D, Matatall KA, Le DT, Kain B, Long X, Kus P, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNgamma signaling. Cell stem cell. 2021;28:1428\u201342.e6.","journal-title":"Cell stem cell"},{"key":"2850_CR5","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood.2022016835","volume":"141","author":"F Caiado","year":"2023","unstructured":"Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives Tet2+\/- clonal hematopoiesis via IL-1 signaling. Blood. 2023;141:886\u2013903.","journal-title":"Blood"},{"key":"2850_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","volume":"23","author":"Z Cai","year":"2018","unstructured":"Cai Z, Kotzin JJ, Ramdas B, Chen S, Nelanuthala S, Palam LR, et al. Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis. Cell Stem Cell. 2018;23:833\u201349.e5.","journal-title":"Cell Stem Cell"},{"key":"2850_CR7","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","volume":"34","author":"AAZ Dawoud","year":"2020","unstructured":"Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34:2660\u201372.","journal-title":"Leukemia"},{"key":"2850_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/bloodadvances.2023011262","volume":"8","author":"AJ Stonestrom","year":"2024","unstructured":"Stonestrom AJ, Menghrajani KN, Devlin SM, Franch-Exposito S, Ptashkin RN, Patel SY, et al. High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer. Blood Adv. 2024;8:846\u201356.","journal-title":"Blood Adv"},{"key":"2850_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","volume":"21","author":"CC Coombs","year":"2017","unstructured":"Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell stem cell. 2017;21:374\u201382.e4.","journal-title":"Cell stem cell"},{"key":"2850_CR10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52:1219\u201326.","journal-title":"Nat Genet"},{"key":"2850_CR11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","volume":"132","author":"JD Kahn","year":"2018","unstructured":"Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, et al. PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018;132:1095\u2013105.","journal-title":"Blood"},{"key":"2850_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell stem cell. 2018;23:700\u201313.e6.","journal-title":"Cell stem cell"},{"key":"2850_CR13","doi-asserted-by":"crossref","unstructured":"Takahashi K, Nakada D, Goodell M Distinct landscape and clinical implications of therapy-related clonal hematopoiesis. J Clin Invest. 2024;134.","DOI":"10.1172\/JCI180069"},{"key":"2850_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071\u20138.","journal-title":"Nature"},{"key":"2850_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1101\/gad.1291305","volume":"19","author":"X Lu","year":"2005","unstructured":"Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005;19:1162\u201374.","journal-title":"Genes Dev"},{"key":"2850_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/sj.onc.1209927","volume":"26","author":"M Oliva-Trastoy","year":"2007","unstructured":"Oliva-Trastoy M, Berthonaud V, Chevalier A, Ducrot C, Marsolier-Kergoat MC, Mann C, et al. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene. 2007;26:1449\u201358.","journal-title":"Oncogene"},{"key":"2850_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ajhg.2019.06.005","volume":"105","author":"V Tiwari","year":"2019","unstructured":"Tiwari V, Wilson DM. 3rd. DNA Damage and Associated DNA Repair Defects in Disease and Premature Aging. Am J Hum Genet. 2019;105:237\u201357.","journal-title":"Am J Hum Genet"},{"key":"2850_CR18","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","volume":"286","author":"DW Bell","year":"1999","unstructured":"Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999;286:2528\u201331.","journal-title":"Science"},{"key":"2850_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75:1131\u20135.","journal-title":"Am J Hum Genet"},{"key":"2850_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1086\/341943","volume":"71","author":"P Vahteristo","year":"2002","unstructured":"Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002;71:432\u20138.","journal-title":"Am J Hum Genet"},{"key":"2850_CR21","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1126\/science.287.5459.1824","volume":"287","author":"A Hirao","year":"2000","unstructured":"Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000;287:1824\u20137.","journal-title":"Science"},{"key":"2850_CR22","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1093\/emboj\/cdf506","volume":"21","author":"H Takai","year":"2002","unstructured":"Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 2002;21:5195\u2013205.","journal-title":"EMBO J"},{"key":"2850_CR23","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1128\/MCB.22.18.6521-6532.2002","volume":"22","author":"A Hirao","year":"2002","unstructured":"Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol. 2002;22:6521\u201332.","journal-title":"Mol Cell Biol"},{"key":"2850_CR24","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.jid.2018.05.015","volume":"138","author":"Y Tanoue","year":"2018","unstructured":"Tanoue Y, Toyoda T, Sun J, Mustofa MK, Tateishi C, Endo S, et al. Differential Roles of Rad18 and Chk2 in Genome Maintenance and Skin Carcinogenesis Following UV Exposure. J Invest Dermatol. 2018;138:2550\u20137.","journal-title":"J Invest Dermatol"},{"key":"2850_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41586-022-05448-9","volume":"612","author":"MD Kessler","year":"2022","unstructured":"Kessler MD, Damask A, O\u2019Keeffe S, Banerjee N, Li D, Watanabe K, et al. Common and rare variant associations with clonal haematopoiesis phenotypes. Nature. 2022;612:301\u20139.","journal-title":"Nature"},{"key":"2850_CR26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.celrep.2016.09.092","volume":"17","author":"MC Gundry","year":"2016","unstructured":"Gundry MC, Brunetti L, Lin A, Mayle AE, Kitano A, Wagner D, et al. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR\/Cas9. Cell Rep. 2016;17:1453\u201361.","journal-title":"Cell Rep"},{"key":"2850_CR27","doi-asserted-by":"crossref","unstructured":"Shi X, Jiang Y, Kitano A, Hu T, Murdaugh RL, Li Y, et al. Nuclear NAD(+) homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. Sci Adv. 2021;7.","DOI":"10.1126\/sciadv.abf3895"},{"key":"2850_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44718-0","volume":"15","author":"YJ Tseng","year":"2024","unstructured":"Tseng YJ, Kageyama Y, Murdaugh RL, Kitano A, Kim JH, Hoegenauer KA, et al. Increased iron uptake by splenic hematopoietic stem cells promotes TET2-dependent erythroid regeneration. Nature Commun. 2024;15:538.","journal-title":"Nature Commun"},{"key":"2850_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, et al. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep. 2016;17:1193\u2013205.","journal-title":"Cell Rep"},{"key":"2850_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15:554.","journal-title":"Genome Biol"},{"key":"2850_CR31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.stem.2023.09.011","volume":"30","author":"CW Chen","year":"2023","unstructured":"Chen CW, Zhang L, Dutta R, Niroula A, Miller PG, Gibson CJ, et al. SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation. Cell Stem Cell. 2023;30:1503\u201319.e8.","journal-title":"Cell Stem Cell"},{"key":"2850_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","volume":"11","author":"HC Reinhardt","year":"2007","unstructured":"Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage. Cancer Cell. 2007;11:175\u201389.","journal-title":"Cancer Cell"},{"key":"2850_CR33","doi-asserted-by":"crossref","unstructured":"Zhang L, Hsu JI, Braekeleer ED, Chen CW, Patel TD, Martell AG, et al. SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells. eLife. 2024;12.","DOI":"10.7554\/eLife.91611"},{"key":"2850_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stem.2014.04.016","volume":"15","author":"I Beerman","year":"2014","unstructured":"Beerman I, Seita J, Inlay MA, Weissman IL, Rossi DJ. Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell. 2014;15:37\u201350.","journal-title":"Cell Stem Cell"},{"key":"2850_CR35","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","volume":"20","author":"A Unnikrishnan","year":"2017","unstructured":"Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, et al. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. Cell Rep. 2017;20:572\u201385.","journal-title":"Cell Rep"},{"key":"2850_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41586-022-05575-3","volume":"613","author":"JL Johnson","year":"2023","unstructured":"Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, et al. An atlas of substrate specificities for the human serine\/threonine kinome. Nature. 2023;613:759\u201366.","journal-title":"Nature"},{"key":"2850_CR37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/MCB.01799-07","volume":"28","author":"SS Palii","year":"2008","unstructured":"Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2\u2019-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008;28:752\u201371.","journal-title":"Mol Cell Biol"},{"key":"2850_CR38","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2:1002\u201317.","journal-title":"Nat Cancer"},{"key":"2850_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552\u20135.","journal-title":"Nature"},{"key":"2850_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.stem.2010.03.002","volume":"6","author":"T Bondar","year":"2010","unstructured":"Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell stem cell. 2010;6:309\u201322.","journal-title":"Cell stem cell"},{"key":"2850_CR41","doi-asserted-by":"crossref","unstructured":"Bernstein N, Spencer Chapman M, Nyamondo K, Chen Z, Williams N, Mitchell E, et al. Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis. Nat Genet. 2024.","DOI":"10.1038\/s41588-024-01755-1"},{"key":"2850_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg0898","volume":"9","author":"C Emori","year":"2023","unstructured":"Emori C, Boucher Z, Bolcun-Filas E. CHEK2 signaling is the key regulator of oocyte survival after chemotherapy. Sci Adv. 2023;9:eadg0898.","journal-title":"Sci Adv"},{"key":"2850_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.1247671","volume":"343","author":"E Bolcun-Filas","year":"2014","unstructured":"Bolcun-Filas E, Rinaldi VD, White ME, Schimenti JC. Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway. Science. 2014;343:533\u20136.","journal-title":"Science"},{"key":"2850_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/bjh.13559","volume":"173","author":"H Janiszewska","year":"2016","unstructured":"Janiszewska H, Bak A, Hartwig M, Kuliszkiewicz-Janus M, Calbecka M, Jazwiec B, et al. The germline mutations of the CHEK2 gene are associated with an increased risk of polycythaemia vera. Br J Haematol. 2016;173:150\u20132.","journal-title":"Br J Haematol"},{"key":"2850_CR45","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3324\/haematol.2011.049494","volume":"97","author":"H Janiszewska","year":"2012","unstructured":"Janiszewska H, Bak A, Pilarska M, Heise M, Junkiert-Czarnecka A, Kuliszkiewicz-Janus M, et al. A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations. Haematologica. 2012;97:366\u201370.","journal-title":"Haematologica"},{"key":"2850_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.leukres.2018.05.013","volume":"70","author":"H Janiszewska","year":"2018","unstructured":"Janiszewska H, Bak A, Skonieczka K, Jaskowiec A, Kielbinski M, Jachalska A, et al. Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML. Leuk Res. 2018;70:74\u20138.","journal-title":"Leuk Res"},{"key":"2850_CR47","doi-asserted-by":"crossref","unstructured":"Stubbins RJ, Arnovitz S, Vagher J, Asom A, Perpich M, Pies M, et al. Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants. Leukemia. 2025.","DOI":"10.1038\/s41375-025-02635-1"},{"key":"2850_CR48","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-019-1765-3","volume":"575","author":"DJ Thompson","year":"2019","unstructured":"Thompson DJ, Genovese G, Halvardson J, Ulirsch JC, Wright DJ, Terao C, et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature. 2019;575:652\u20137.","journal-title":"Nature"},{"key":"2850_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S0165-4608(99)00042-4","volume":"114","author":"A Smith","year":"1999","unstructured":"Smith A, Watson N, Sharma P. Frequency of trisomy 15 and loss of the Y chromosome in adult leukemia. Cancer Genet Cytogenet. 1999;114:108\u201311.","journal-title":"Cancer Genet Cytogenet"},{"key":"2850_CR50","doi-asserted-by":"crossref","unstructured":"Zhang Q, Zhao L, Yang Y, Li S, Liu Y, Chen C Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis. JCI Insight. 2022;7.","DOI":"10.1172\/jci.insight.153768"},{"key":"2850_CR51","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S0140-6736(73)92108-9","volume":"2","author":"J Grozdea","year":"1973","unstructured":"Grozdea J, Kessous A, Colombies P. Leukaemia and loss of Y chromosome. Lancet. 1973;2:506.","journal-title":"Lancet"},{"key":"2850_CR52","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, Lubbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35:1873\u201389.","journal-title":"Leukemia"},{"key":"2850_CR53","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/cncr.33689","volume":"127","author":"K Kim","year":"2021","unstructured":"Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127:3772\u201381.","journal-title":"Cancer"},{"key":"2850_CR54","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.3324\/haematol.2014.104760","volume":"99","author":"C Muller-Thomas","year":"2014","unstructured":"Muller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, et al. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2014;99:e179\u201381.","journal-title":"Haematologica"},{"key":"2850_CR55","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1080\/10428194.2020.1864354","volume":"62","author":"JM Middeke","year":"2021","unstructured":"Middeke JM, Teipel R, Rollig C, Stasik S, Zebisch A, Sill H, et al. Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis. Leuk Lymphoma. 2021;62:1432\u201340.","journal-title":"Leuk Lymphoma"},{"key":"2850_CR56","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","volume":"38","author":"C Bally","year":"2014","unstructured":"Bally C, Ades L, Renneville A, Sebert M, Eclache V, Preudhomme C, et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leuk Res. 2014;38:751\u20135.","journal-title":"Leuk Res"},{"key":"2850_CR57","doi-asserted-by":"publisher","first-page":"55264","DOI":"10.18632\/oncotarget.10526","volume":"7","author":"SH Jung","year":"2016","unstructured":"Jung SH, Kim YJ, Yim SH, Kim HJ, Kwon YR, Hur EH, et al. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget. 2016;7:55264\u201375.","journal-title":"Oncotarget"},{"key":"2850_CR58","doi-asserted-by":"publisher","first-page":"14172","DOI":"10.18632\/oncotarget.7290","volume":"7","author":"K Takahashi","year":"2016","unstructured":"Takahashi K, Patel K, Bueso-Ramos C, Zhang J, Gumbs C, Jabbour E, et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016;7:14172\u201387.","journal-title":"Oncotarget"},{"key":"2850_CR59","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1182\/bloodadvances.2021005859","volume":"6","author":"RR Schimmer","year":"2022","unstructured":"Schimmer RR, Kovtonyuk LV, Klemm N, Fullin J, Stolz SM, Mueller J, et al. TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood Adv. 2022;6:3201\u20136.","journal-title":"Blood Adv"},{"key":"2850_CR60","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016;375:2023\u201336.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02850-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02850-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02850-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:02:43Z","timestamp":1772614963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02850-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02850-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The animal experiments were approved by BCM Institutional Animal Care and Use Committees (protocol #AN-5858). The study does not include human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}